Company profile
Phrontline Biopharma
Privately held: no public share price (Private bispecific-ADC biotech; $60M Pre-A+ round Nov 2025, no exchange listing of its own. [resolved 2026-08-05 by resolve-null-is-public; source: https://www.prnewswire.com/news-releases/phrontline-biopharma-raises-60-million-in-pre-a-financing-to-advance-global-development-of-bispecific-and-dual-payload-adcs-302625090.html]) · China
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | EGFR and B7-H3 (CD276), dualAntibody–drug conjugate | Non-Small Cell Lung Cancer |
Upcoming events
Research
Sign in to access ResearchUnlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Research
Sign in to access ResearchUnlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.